Biotech Values

[iwfal]

HCV - 1st trial with shot at 100% cure:

BMS-790052 (NS5A Inhibitor) and BMS-650032 (NS3 Protease Inhibitor)

and IFN-Lambda +/- Rib

Reminder that 790052 and 650032 are the two DAAs that, without SOC, have shown the best effect in nulls. But still had >50% breakthroughs. In comparison the other arm of the same trial (same 2 DAAs plus SOC) had 100% SVR12.

http://clinicaltrials.gov/ct2/show/NCT01309932?term=790052+650032&rank=1

I'd say that BMY is aiming to have the first 100% (or close enough) cure to make it to market. And possibly with lower side effects that the competitors that have lower cure rates.